2022 World Conference on Lung Cancer (ePosters)-EP08.01-100. Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic

EP08.01-100. Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic

Back to course

Pdf Summary

Researchers in China have found that the composition of gut microbiome can influence the response to immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). ICIs targeting the PD-1/PD-L1 axis have shown efficacy in some advanced NSCLC patients, but primary resistance is still a problem. The researchers collected fecal and blood samples from 44 NSCLC patients receiving PD-1-based immunotherapy and analyzed the gut microbiome using metagenomic sequencing and metabolomic analyses. They found that Bifidobacterium bifidum, a specific strain of gut microbiome, modulates alpha-galactosidase, which in turn affects the efficacy of PD-1-based immunotherapy against advanced NSCLC. The researchers believe that their findings have potential implications for understanding and overcoming primary resistance to ICIs in advanced NSCLC patients.

Asset Subtitle

Xiaorong Dong

Meta Tag

Speaker Xiaorong Dong

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

China

gut microbiome

immune checkpoint inhibitors

non-small cell lung cancer

NSCLC

PD-1/PD-L1 axis

primary resistance

fecal samples

metagenomic sequencing

metabolomic analyses